Allied Investment Advisors LLC Has $8.02 Million Stock Holdings in Pfizer Inc. $PFE

Allied Investment Advisors LLC lifted its stake in Pfizer Inc. (NYSE:PFE) by 8.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 330,727 shares of the biopharmaceutical company’s stock after acquiring an additional 26,843 shares during the quarter. Allied Investment Advisors LLC’s holdings in Pfizer were worth $8,017,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of PFE. GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer in the first quarter worth $27,000. North Capital Inc. bought a new stake in Pfizer in the first quarter worth $28,000. Bayforest Capital Ltd bought a new stake in Pfizer in the first quarter worth $28,000. Harbor Asset Planning Inc. bought a new stake in Pfizer in the second quarter worth $29,000. Finally, Horizon Financial Services LLC bought a new stake in Pfizer in the first quarter worth $35,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Up 0.5%

NYSE PFE opened at $24.79 on Friday. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The stock’s 50 day moving average is $24.87 and its two-hundred day moving average is $24.17. The company has a market capitalization of $140.92 billion, a price-to-earnings ratio of 13.18, a PEG ratio of 0.82 and a beta of 0.55. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $29.17.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. Pfizer’s dividend payout ratio (DPR) is currently 91.49%.

Analyst Ratings Changes

A number of brokerages recently issued reports on PFE. UBS Group reiterated a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a report on Wednesday, October 1st. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Bank of America upped their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Citigroup upped their price target on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a report on Wednesday, August 6th. Finally, Morgan Stanley decreased their price target on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $28.13.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.